Phase 2 Study to Evaluate ALN-TTRSC (Revusiran) in Patients With Transthyretin (TTR) Cardiac Amyloidosis
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Layout table for eligibility information
Ages Eligible for Study:
18 Years to 80 Years (Adult, Older Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
TTR cardiac amyloidosis;
Women of child-bearing potential (WOCBP) must have a negative pregnancy test, cannot be breast feeding, and must be willing to use 2 highly effective methods of contraception;
Male subjects agree to use appropriate contraception;
Adequate blood counts, liver, renal and heart function;
Adequate Karnofsky performance status;
Adequate New York Heart Association (NYHA) Classification Score;
Clinically stable on heart medications;
Adequate 6-minute walk test;
Willing to give written informed consent and are willing to comply with the study requirements.
Known human immunodeficiency virus (HIV) positive status or known or suspected systemic bacterial, viral, parasitic, or fungal infection;
Subjects with a history of multiple drug allergies or intolerance to SC injection;
Received an investigational agent other than tafamidis, diflunisal, doxycycline or tauroursodeoxycholic acid, or an investigational device within 30 days prior to first dose of study;
Uncontrolled hypertension, ischemic heart disease or cardiac arrhythmia;
Untreated hypo- or hyperthyroidism;
Prior major organ transplant;
Considered unfit for the study by the Principal Investigator.